Aravive — Investor Presentation (May 2021)
39 slides from Aravive's investor presentation, May 6, 2021
Slide 1: Corporate Presentation May 2021: Halting Disease Progression in its Tracks
Corporate Presentation May 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) © 2021 Aravive, Inc. Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward Looking Statements © 2021 Aravive, Inc. 2 This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- l
Slide 3: AVB-500 development program focused on difficult-to-treat cancers
© 2021 Aravive, Inc. 3 AVB-500 development program focused on difficult-to-treat cancers with high unmet medical needs Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival Proprietary, differentiated first-in-class therapeutic targeting and inhibit
Slide 4: Experienced Management and Board of Directors
Experienced Management and Board of Directors Board of Directors Senior Management CEO Gail McIntyre, Ph.D., DABT CMO Reshma Rangwala, M.D., Ph.D. Chairman of the Board Fred Eshelman, Pharm D. Director Amato Giaccia, Ph.D. Director Michael Rogers Director Eric Zhang CFO Vinay Shah SVP of Data Scienc
Slide 5: AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway
AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway and Blocking the Signaling AVB-500 © 2021 Aravive, Inc. 5
Slide 6: GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth
GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its recept
Slide 7: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
© 2021 Aravive, Inc. 7 GAS6 & AXL Expression Associated with Poor Survival in Many Cancers “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” Wu G, et al. Molecular insights of Gas6/TAM in cancer development and therapy; Cell Death and Disease (2017) 8, e2700. AXL
Slide 8: AVB-500: Addresses Limitations of Other Therapies
As an engineered decoy receptor with 200-fold higher affinity for GAS6 versus natural GAS6/AXL interaction, AVB-500 provides potent & selective inhibition of this signaling pathway. Other approaches targeting GAS6/AXL signaling have drawbacks: Tyrosine Kinase Inhibitors lack selectivity, leading to
Slide 9: Clinical Pipeline
Forward-Looking Statements Clinical Pipeline Potential Opportunities for Expansion in Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 3 Phase 2 © 2021 Aravive, Inc. 9 Anti-CTGF AVB-500 AVB-500 Investigator Sponsored Trials
Slide 10: Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer
Forward-Looking Statements Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR RELATIVE SURVIVAL (9-12 months PROC) LESS
Slide 11: AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data
AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data AVB-500 q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on AVB-500 monotherapy PROC = platinum-resistant ovarian cancer iDMC= Independent Da
Slide 12: Time on Treatment and Depth of Response for AVB-500 + Paclitaxel Patients
Time on Treatment and Depth of Response for AVB-500 + Paclitaxel Patients (10 and 15mg/kg groups) © 2021 Aravive, Inc. 12
Slide 13: AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups
AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups Note: AVB-500 + PAC and >MEC in bev naïve patients (n=7): mPFS 9.1 months and ORR of 71% Note: AVB-500 + PAC and <MEC: mPFS 2.8 months * Study ongoing so data can change; ** MEC = minimal efficacious concentration (13.8mg/L) For referen
Slide 14: sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo
sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo Serum levels of sAXL/GAS6 ratio (potential biomarker) correlated with response to AVB-500 + Chemo Building dataset to understand prognostic ability of biomarker May identify tumors that are dependent on the GAS6/AXL pathway Investigating in
Slide 15: Promising Responses in Patients > MEC with Poor Prognostic Indicators
Promising Responses in Patients > MEC with Poor Prognostic Indicators CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PLATINUM FREE INTERVAL** (N=21) CLINICAL RESPONSE OF CHEMOTHERAPY IN 3rd LINE AND 4th LINE*** (N=99) *All doses and both chemo cohorts; **Historical data from Cancer Chemothe
Slide 16: Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg
Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg 5/5 patients at 15mg/kg demonstrated clinical benefit: Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their first CT scan, following four doses
Slide 17: Strong Safety Profile of AVB-500
Strong Safety Profile of AVB-500 Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomit
Slide 18: Competitive Advantages of AVB-500 in PROC
Competitive Advantages of AVB-500 in PROC: Favorable Safety Profile and Compelling Anti-Tumor Activity Favorable Safety Profile to Date NO DLTs like chemotherapies and ADCs NO dose reductions or discontinuations to manage toxicities NO toxicities that have been seen with ADCs: neutropenia, ocular to
Slide 19: Potentially More Favorable Benefit/Risk Profile vs Competitors
Potentially More Favorable Benefit/Risk Profile vs Competitors For illustrative purposes only, Data not generated from comparative study. Variation in study design including patient eligibility, response criteria, and assessment can affect outcomes and limit comparisons across studies. **Sources: Me
Slide 20: AVB-500 Phase 3 Adaptive Registration Trial Design in PROC
Forward-Looking Statements AVB-500 Phase 3 Adaptive Registration Trial Design in PROC © 2021 Aravive, Inc. 20 FDA Feedback: Study could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time; AVB-500 granted Fast Track Designation by FDA in PROC in 20
Slide 21: Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma
Forward-Looking Statements Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma; Patients Have Very Poor Survival Rates Renal Cell Carcinoma 15% ~76,100 RESISTANCE To CHEMO LESS THAN 5-YEAR RELATIVE SURVIVAL for metastatic renal cancer NEW CASES and ~13,800 deaths expected in the U.S. in 20
Slide 22: Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC
Forward-Looking Statements Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC GAS6/AXL in clear cell Renal Cell Carcinoma (ccRCC)1 AXL plays significant role in ccRCC invasion & metastasis AXL highly expressed in aggressive ccRCC tumors and associated with poor outcome GAS6/AXL signaling
Slide 23: Single Agent Activity in Highly Metastatic Renal Model (SN12L1)
Forward-Looking Statements Single Agent Activity in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk 10 mg/kg administered QOD Rankin et al, PNAS, September 16, 2014, vol. 111, no. 37, 13373–13378 Note: S6-1 and AVB-S6 are related AXL decoy proteins; both in S6 family Th
Slide 24: Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX
Forward-Looking Statements Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX AVB-500/Pazopanib Combination Significantly Reduced Growth Rate in TKI-Resistant Renal Patient-Derived Xenograft Models Xiao et al, Cancer Res 2019;79:5758–68; *note AVB-S6 is AVB-500 © 2021 Aravive, In
Slide 25: AVB-500 + Cabozantinib Phase 1b/2 Trial Design in ccRCC
Forward-Looking Statements AVB-500 + Cabozantinib Phase 1b/2 Trial Design in ccRCC Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD Histologically confirmed metastatic ccRCC and patient has progressed on/afte
Slide 26: Planned Third Indication: AVB-500 in Pancreatic Cancer
Planned Third Indication: AVB-500 in Pancreatic Cancer; High Unmet Medical Need to Improve Patient Survival © 2021 Aravive, Inc. 26 Sources: Pancreatic Cancer Overview | American Association for Cancer Research (aacr.org); World Health Organization (who.int) Pancreatic Cancer ~11% 5-YEAR RELATIVE SU
Slide 27: Strong Biological Rationale for AVB-500 in Pancreatic Cancer
© 2021 Aravive, Inc. 27 Preclinical data demonstrated increased survival in combination with gemcitabine, decreased fibrosis, and decreased tumor weight in orthotopic models AVB-500 in combination with paclitaxel demonstrated compelling clinical activity in PROC Studies have reported AXL expression
Slide 28: High Affinity AXL Decoy Proteins Decrease Fibrosis, Prolong Survival
High Affinity AXL Decoy Proteins Decrease Fibrosis, Prolong Survival, and Decrease Tumor Weight Alone or in Combination with Gemcitabine in Pancreatic Models – Compelling Pre-Clinical Data LM-P Tumor (Kras, p53 mutant) Implanted in Tail of Pancreas Survival increased 3-fold Fibrosis dramatically dec
Slide 29: AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b Trial Design
Forward-Looking Statements AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Cancer © 2021 Aravive, Inc. 29 Population: Patients (n=20) with advanced or metastatic pancreatic cancer eligible to receive gemcitabine + nab-paclita
Slide 30: Planned Controlled, Randomized Phase 2 Trial in Pancreatic Cancer
© 2021 Aravive, Inc. 30 AVB-500 + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Cancer Population: Patients (n=60) with advanced or metastatic pancreatic cancer eligible to receive gemcitabine + nab-paclitaxel as first-line treatment
Slide 31: Development Strategy: Conduct Additional Trials to Expand Pipeline
© 2021 Aravive, Inc. 31 Preclinical data suggests that AVB-500 has potential in multiple combinations and indications: Reduction of metastases to lung (breast and renal models) Reduction of metastases to peritoneum (ovarian and pancreatic models) Decreased fibrosis in pancreatic model Decreased meta
Slide 32: AVB-500: Large Market Opportunities in PROC, ccRCC, Pancreatic Cancer & Other Indications
AVB-500: Large Market Opportunities in PROC, ccRCC, Pancreatic Cancer & Other Indications 2L-4L platinum-resistant ovarian cancer (PROC), high grade serous patients 2L advanced/metastatic clear cell renal cell carcinoma (ccRCC) patients Adenocarcinoma – Metastatic 1L, eligible to receive gemcitabine
Slide 33: Strategic Collaboration with WuXi Biologics for High-Affinity Bispecific Antibodies
Forward-Looking Statements Strategic Collaboration with WuXi Biologics for High-Affinity Bispecific Antibodies Objective is to identify/develop novel, high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), targeting cancer/fibrosis using WuXiBody™ pla
Slide 34: 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China
Forward-Looking Statements 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China for Oncology Indications Exclusive collaboration and license agreement for development & commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Great
Slide 35: Financial Summary
Forward-Looking Statements Financial Summary * Data as of 3/31/2021 © 2021 Aravive, Inc. 35 $78.7 million cash and cash equivalents 20.3 million shares outstanding No debt Cash runway expected to fund current operating plans into 2H 2022 Achieved first clinical milestone with 3D Medicines and expect
Slide 36: Aravive Top Shareholders
Aravive Top Shareholders Insiders, Institutional Shareholders Make Up approx. 70% of Our Outstanding Shares © 2021 Aravive, Inc. 36 * As per SEC filings – 13D, 13F, 13G, Forms 3 and Form 4, Proxy ** As of 12/31/2020, adjusted for Eshelman Ventures investment in Feb-21
Slide 37: Upcoming Key Milestones Advancing Our Clinical Development Program
Forward-Looking Statements Upcoming Key Milestones Advancing Our Clinical Development Program © 2021 Aravive, Inc. 37 Q3 2021 Q4 2021 Q1 2022 2021 and Beyond Completion of enrollment in Phase 1b ccRCC trial Initiation of Phase 2 ccRCC trial Planned initiation of Phase 1b Pancreatic Cancer trial Inte
Slide 38: Advancing AVB-500 Clinical Trial Program & Pursuing Additional Pipeline Expansion
© 2021 Aravive, Inc. 38 Focused on difficult-to-treat cancers: AVB-500 lead indication in advanced stage ovarian cancer; registrational Phase 3 clinical trial ongoing Advancing AVB-500 Clinical Trial Program & Pursuing Additional Pipeline Expansion Opportunities AVB-500 targets and inhibits GAS6/AXL
Slide 39: Thank you!
Thank you! Halting Disease Progression in its Tracks © 2021 Aravive, Inc.